Gastric lipase Inhibitors
1 drugsAbout Gastric lipase
Gastric lipase, secreted by chief cells in the stomach, initiates digestion of dietary fats, especially triglycerides. While pancreatic lipase is the major enzyme, gastric lipase is crucial in infants and those with pancreatic insufficiency.
Gastric lipase is a drug target for metabolic disorders, with inhibition reducing dietary fat absorption for weight loss. Currently, there is no genetic evidence directly linking gastric lipase to specific diseases.
Gastric lipase is targeted by one FDA-approved drug, XENICAL (orlistat), a small molecule from CHEPLAPHARM approved in 1999 for metabolic indications.
Strategic Insights
ℹ️ How we calculate- White space opportunity in Endometrial Cancer with only 1 trials.
- phase2 represents biological uncertainty with 50% completion.
Top Gastric lipase Drugs
CHEPLAPHARM is the only company with an approved drug targeting gastric lipase.
Low competition suggests opportunity, but also highlights potential market risk and entry barriers.
Gastric lipase Drug Modality Landscape
Modalities
Routes of Administration
Only one approved drug targets Gastric lipase, using small molecule modality.
Explore alternative modalities like antibodies or peptides to differentiate from existing therapies.
Gastric lipase Clinical Trials 24 trials
Completion by Phase
| Phase | Total | Completed | Failed | Active | Completion |
|---|---|---|---|---|---|
| Phase 1 | 2 | 2 | 0 | 0 | 100% |
| Phase 2 | 9 | 4 | 2 | 3 | 67% |
| Phase 3 | 3 | 3 | 0 | 0 | 100% |
| Phase 4 | 10 | 6 | 2 | 2 | 75% |
Top Sponsors
By Modality
Top Conditions
Top Drugs
Gastric lipase Drug Approval Timeline (1999 - 1999)
The first and only drug, XENICAL, was approved in 1999.
The lack of recent approvals indicates potential saturation or challenges in developing new gastric lipase inhibitors.
Pro Intelligence Preview
Deep insights for drug target analysis
Competitive Landscape
- • 1 companies competing
- • Market share by company
Full Drug Portfolio
- • All 1 approved drugs
- • Approval dates & indications
Genetic Validation
- • Full genetic evidence table
- • Effect sizes & directions
Approval Timeline
- • Full 1-drug timeline
- • First-of-modality markers
Clinical Trials Analysis
- • Competition: High (15 sponsors)
- • White space: 10 underexplored indications
- • Success rates by condition
Full summary • All drugs • Genetic evidence • Trials • Timeline
How We Calculate These Metrics
Target Attractiveness Score
A 0-100 score based on trial activity, sponsor diversity, and completion rates. Calculated from 20 clinical trials targeting Gastric lipase.
Completion rate: Percentage of trials that reached their planned endpoint. Trials terminated early, withdrawn, or suspended are not counted—these often indicate safety issues, lack of efficacy, or strategic pivots.
- Highly Attractive (80+): High trial activity, many sponsors, strong completion rates
- Attractive (60-79): Good trial activity and validation
- Moderate (40-59): Moderate interest from sponsors
- Low (under 40): Limited trial activity or validation concerns
Strategic Insights
Auto-generated insights based on trial analytics including competition intensity, white space opportunities, modality shifts, and failure patterns. We analyze trial sponsors, phases, indications, and outcomes.
Risk Signals
- High Competition: Many sponsors competing for this target (may reduce market opportunity)
- High Failure Risk: Low trial completion rates suggest development challenges
- Low Validation: Limited trial activity or poor outcomes indicate uncertain viability
- White Space Available: Underexplored indications present opportunities